At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 76 enrolled
Drug / intervention
Cebranopadoldrug
Likely dose
Cebranopadol 600 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial
In Brief
A Phase 3 clinical trial evaluating Cebranopadol for Pain and 2 related conditions. Completed, enrolled 76 participants across 22 sites in 10 countries.
Detailed Summary
The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Neoplasms, Chronic Pain
CountriesAustria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedJan 2014
Primary CompletionApr 2016
Study CompletionMay 2016
TodayJul 2026
First PostedJan 9, 2014
Enrollment StartDec 18, 2013
Primary CompletionApr 1, 2016
Study CompletionMay 3, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.5 years ago
Interventions
Cebranopadoldrug
Film-coated tablet; strengths: 200, 400, or 600 µg